Belantamab Mafodotin

• A multicenter phase 2 study of Belantamab mafodotin and Mezigdomide in combination with a phase Ib Safety run in patients with relapsed mult… Pending
  2025-520976-25-00 Phase II 1 country Centre Hospitalier Universitaire De Saint Etienne
• A study to evaluate the efficacy and safety of belantamab mafodotin in combination with standard of care in participants aged 18 years and o… Pending
  2025-523117-28-00 Phase II 5 countries Glaxosmithkline Research & Development Limited
• A trial aiming to investigate the safety and efficacy of a new drug in patients with primary immune thrombocytopenia previously treated with… Recruiting
  2023-509131-12-01 Phase II 1 country Hellenic Society Of Hematology
• Phase 3 study of belantamab mafodotin, lenalidomide, and dexamethasone (BRd) versus daratumumab, lenalidomide, and dexamethasone (DRd) in pa… Recruiting
  2024-516030-35-00 Phase III 11 countries Glaxosmithkline Research & Development Limited
• A phase 1/2, dose and schedule evaluation study to investigate the safety and clinical activity of belantamab mafodotin administered in comb… Ended
  2024-517723-39-00 Phase II 1 country Hellenic Society Of Hematology
• Phase 2 study of belantamab mafodotin in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma Ended
  2024-516250-22-00 Phase II 1 country Ceska Myelomova Skupina z.s.
• A PHASE 1/2, DOSE AND SCHEDULE EVALUATION STUDY TO INVESTIGATE THE SAFETY AND CLINICAL ACTIVITY OF BELANTAMAB MAFODOTIN ADMINISTERED IN COMB… Ended
  2024-516147-32-00 Phase I/II 1 country Hellenic Society Of Hematology
• Belantamab Mafodotin in combination with Daratumumab, Lenalidomide and Dexamethasone for the treatment of patients with newly diagnosed mul… Ended
  2024-515634-32-00 Phase I/II 1 country Hellenic Society Of Hematology
• An open label, multicenter, phase I/II study of belantamab mafodotin in combination with Kd for the treatment of relapsed myeloma patients, … Ended
  2024-517006-28-00 Phase I/II 1 country Fundacion PETHEMA
• Isatuximab in combination with belantamab mafodotin and dexamethasone in RRMM. Ended
  2024-514989-40-00 Phase I/II 3 countries Sanofi-Aventis Recherche & Developpement
• A phase 1/2, dose and schedule evaluation study to investigate the safety and clinical activity of Belantamab Mafodotin administered in comb… Ended
  2024-515988-55-00 Phase II 1 country Hellenic Society Of Hematology
• A study of a combination of Belantamab Mafodotin with Pomalidomide and Dexamethasone (B-Pd) compared to Bortezomib with Pomalidomide and Dex… Ended
  2023-506877-37-00 Phase III 7 countries Glaxosmithkline Research & Development Limited
• A study of belantamab mafodotin compared to a combination of pomalidomide and dexamethasone in participants with relapsed/refractory multipl… Ended
  2023-508962-14-00 Phase III 10 countries Glaxosmithkline Research & Development Limited
• Phase III study of GSK2857916, bortezomib, and dexamethasone versus daratumumab, bortezomib, and dexamethasone in participants with relapsed… Ended
  2023-510537-28-00 Phase III 9 countries Glaxosmithkline Research & Development Limited
• Platform Study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination with Anti-Cancer Treatments in Participants with RRMM. Ended
  2023-509550-55-00 Phase I (FiH) 4 countries Glaxosmithkline Research & Development Limited
• An open label, multicenter, phase II study of belantamab mafodotin in combination with VRd for the treatment of newly diagnosed transplant e… Ended
  2024-516130-35-00 Phase II 1 country Fundacion Pethema
• Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants with Relapsed or Refractory Multiple Myeloma (DREAM… Ended
  2023-508213-16-00 Phase II 7 countries Glaxosmithkline Research & Development Limited
• Belantamab Mafodotin in patients with relapsed or refractory AL amyloidosis Ended
  2024-513075-40-00 Phase II 5 countries Emn Trial Office S.r.l. Impresa Sociale; European Myeloma Network B.V.

Showing 1–18 of 18 trials